Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer

Archives of Medical Science

Volumn 10, Issue 1, 2014, Pages 149-153

  Lu, Yi Zhuo ^a   Deng, An Mei ^b   Li, Liang Hui ^a   Liu, Guo Yan ^a   Wu, Guo Yang ^a  

^a XIAMEN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Phosphorylation; PI3K; PRAS40; Prognosis; Targeted therapy

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHO PRAS40; PROLINE RICH PROTEIN; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STOMACH ADENOCARCINOMA; STOMACH CANCER;

EID: 84900645303     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2013.36927     Document Type: Article

References (14)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-62.
2. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.
3. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
4. Wojciechowska-Durczyńska K, Lewiński A. Phosphoinositide 3-kinase alterations in the thyroid gland-a review study. Arch Med Sci 2009; 5: 10-5.
5. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-83.
6. Arkenau HT. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol 2009; 135: 855-66.
7. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009; 15: 406-20.
8. Andersen JN, Sathyanarayanan S, Di Bacco A, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2010; 2: 43-55.
9. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5: e8.
10. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416-22.
11. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729-34.
12. Nascimento EB, Snel M, Guigas B, et al. Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. Cell Signal 2010; 22: 961-7.
13. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5: e8.
14. McBride SM, Perez DA, Polley MY, et al. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 2010; 97: 33-40.